Table 4.

The clinicopathologic findings of 14 patients with ALK rearrangement.

Patient No.	Sex	Age	Smoking status	Histology	Stagea	Survival	ALK inhibitors use
1	Female	74	No	Solid adenocarcinoma, signet	IV	Dead,18 M	No
2	Male	33	Yes	Adenosquamous carcinoma	IIa	Dead,21 M	No
3	Male	52	Yes	Solid adenocarcimona, signet	IIIb	Dead,12 M	No
4	Female	69	No	Papillary,solid(signet),cribriform pattern of acinar with mucin	IV	Alive,7Y8M	Yes
5	Female	66	No	Solid adenocarcinoma, signet	IV	Dead,5 M	No
6	Female	56	No	Solid adenocarcinoma, signet	IV	Dead,7 M	No
7	Male	39	Yes	Solid(signet), acinar	IV	Dead, 6Y	Yes
8	Male	58	No	Cribriform pattern of acinar with mucin, solid adenocarcinoma	II	Alive, 5Y11M	Yes
9	Female	67	No	Solid adenocarcinoma, signet	II	Alive, 5Y10M	Yes
10	Female	69	No	Solid adenocarcinoma, signet	III	Unknown	No
11	Female	60	No	Solid(signet), cribriform pattern of acinar with mucin	IV	Alive, 5Y10M	Yes
12	Male	17	No	Solid adenocarcinoma, signet	IV	Dead, 3Y	Yes
13	Male	53	Yes	Solid adenocarcinoma, signet	Ia	Alive, 5Y10M	Yes
14	Male	61	No	Micropapillary with mucin	Ia	Alive, 5Y10M	Yes

^aClinical stage represents stage at initial diagnosis. Stage was determined according to WHO TNM classification of lung carcinomas in 2015.